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product’s value are the economic and humanistic conse-
quences of the new therapy relative to the gold standard.
However, in many circumstances, the patient is unable to
provide an accurate assessment of healthcare resources
consumed or their quality of life and functional status. Re-
searchers have opted for the use of proxies in these in-
stances, under the presumption that a larger sample size in-
creases the power to detect meaningful differences. This
presumption, however, neglects the inaccuracies inherent
in proxy reporting and thus may inhibit the reliability of
the estimates obtained. This workshop will review and
evaluate the use of proxy respondents in the collection of
resource utilization and quality of life data. A critical ex-
amination will be given to their potential influence on study
results. Suggestions for overcoming these issues will also be
presented and discussed. This session is directed at individ-
uals in pharmaceutical firms, contract research organiza-
tions (CROs), and consultant companies responsible for
the design and conduct of pharmacoeconomic evaluations.
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Assessing the impact of disease and the effect of treat-
ment on patient quality of life (QoL) has become of ma-
jor importance both to the pharmaceutical industry and
the medical profession. The last 20 years have seen the
development of a large number of QoL questionnaires,
increasingly being used in clinical trials, with a growing
emphasis on multinational applications. As a result, there
is a continually expanding need for cross-nationally and
cross-culturally valid, reliable and responsive QoL instru-
ments. This course will provide key information and op-
erational solutions to implement health status and QoL
measures in clinical trials. The content of the course will
cover definitions of health status and QoL; types of in-
struments used, including their strengths and weaknesses;
identification of concepts to be measured; and selection
of relevant instruments. The second part of the course
will focus on strategy for instrument development, lin-
guistic validation and psychometric validation, as well as
interpretation guidelines. Participants will acquire a com-
mon baseline understanding of health and QoL evalua-
tions, allowing them to become actively involved in de-
velopment of optimal programs for clinical development
and marketing purposes.
TRACK 4: STUDY METHODS
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An important element in judging the worthiness of a new
drug’s effects is the translation of randomized trial results
to actual clinical practice. A key input is the risk experi-
enced by routinely managed patients. The risk rate is im-
portant, because the relative risk reduction typically esti-
mated in trials only gains meaning when it is applied to
such a reference risk. While the relative risk reduction is
widely believed to be generalizable, the reference risk is not.
In this workshop, an ongoing study, CAPRA (CAPRIE Ac-
tual Practice Rates Analysis) will be used as a case study—
along with other published reports—to examine why con-
sidering information beyond that obtained in a clinical trial
can be critical in assessing the value of a new therapy. The
major reasons practice may diverge from trials, along with
evidence of this fact, will be introduced. The methods for
extending trial results to clinical practice will be demon-
strated and discussed, along with alternative approaches to
estimating actual practice results from clinical trial experi-
ence. The focus will be on the use of epidemiologic studies
and databases such as that from Saskatchewan Health. De-
tails of this analysis of records for 12,931 patients used to
estimate the risk of first subsequent ischemic events (MI, is-
chemic stroke, vascular death) in actual practice will be
shown. The magnitude of the distortion, with special refer-
ence to numbers needed to treat, and the implications for
cost-effectiveness analysis will be presented. All available
information and methods ought to be employed when con-
sidering a new therapy, as it is insufficient to evaluate a new
therapy based on trial results alone.
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Most pharmacoeconomic studies present estimates of the
impact of new treatments on expected lifetime costs and
health outcomes for typical individuals with a given dis-
ease. However, national or local healthcare decision-
makers also need to know what impact the new treat-
ment will have on their annual budgets and on annual
health outcomes for their patient populations. In this
workshop, a method for estimating the population im-
pacts of new treatments is presented. How information
about the impact of a new treatment on individual pa-
tients can be combined with information about the num-
ber and type of patients in the patient population to esti-
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mate the impact of the new treatment on annual budgets
and health outcomes is shown. For chronic diseases, the
impact of a new treatment on annual budget and health
outcomes may change over the first few years, until a new
steady state is reached. How these estimates vary with
different assumptions about the extent of use of the new
treatment is shown. A method for generating these esti-
mates using a model developed to estimate the budget
and health outcome impacts of new HIV treatments for
state- or federally-funded programs is illustrated. Popula-
tion estimates allow healthcare decision-makers to evalu-
ate the impact on their budgets and patient health of 1)
providing the new treatment to their patients, and 2)
ensuring that they have sufficient funds available. This
workshop will be of value both to industry pharmaco-
economists and national and/or local healthcare decision-
makers. How to generate analyses of economic and health
outcomes in a population format that is likely to be of
value for new treatment decisions will be shown.
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Handling survival data in cost-effectiveness (CE) studies
generally implies an assessment of the survival data pre-
sented in clinical trials (measured survival), together with a
long-term prediction of life expectancy for the same pa-
tients (predicted survival). Because different methods are
needed to manage the data of measured survival and of
predicted survival, this workshop will present an overview
of these methods and discuss their relative advantages and
disadvantages. 1. Measured survival: When a single clini-
cal trial is the source of the survival information, tradi-
tional methods for constructing survival curves can be uti-
lized in CE studies. When two or more clinical trials are
available, combining the data requires a survival meta-
analysis. Although the methodology of survival meta-anal-
ysis is still under development, some techniques in this area
have adequately been tested and can therefore be proposed
for general use. 2. Predicted survival: Traditional life-
expectancy calculations remain the mainstay for predicting
survival in healthy subjects or in “cured” patients. Specific
methods, however, are needed for correcting normal life
expectancy predictions on the basis of the presence of a
disease condition. The Gompertz extrapolation technique
can be used for conditions where the chance of cure is min-
imal. Furthermore, other methods have recently been pro-
posed for combining the clinical evidence of a specific
survival pattern with the assignment of a normal life ex-
pectancy to “long term survivors.” This workshop is de-
signed to provide an overview of the foregoing methods; to
report on their use in clinical and economic evaluation;
and to present detailed examples of their application. It is
expected that workshop attendees will be primarily re-
searchers and analysts concerned with clinical and eco-
nomic evaluation, particularly where multi-center collabo-
ration is involved.
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Society’s perspective of costs and benefits of healthcare
programs has been well established in theory and method-
ology of outcomes research. Far less rigorously examined
are issues from the perspective of the payers. For rehabili-
tation programs in Germany, the perspective of Social Old
Age Insurance Funds (SOAIF) is of particular importance.
For the workforce, SOAIF finances most rehabilitative in-
terventions; they finance invalidity pensions in cases where
their insured can no longer participate in the workforce;
and rehabilitation programs are designed to avoid invalid-
ity. In the workshop, theoretical and methodological issues
of a payer’s perspective in general, and of SOAIF in partic-
ular, are discussed. Four perspectives of SOAIF can be dis-
tinguished: 1) minimizing SOAIF’s expenditure—this re-
quires financing rehabilitative intervention in case it can be
assumed that the expenditure for invalidity pensions saved
through an intervention exceeds the expenditure for the in-
tervention itself; 2) minimizing costs and cases of invalidity
according to the (German) social code on rehabilitation—
here the costs of interventions are not considered; 3) maxi-
mizing a social welfare function—as part of social insur-
ance and the welfare state arrangements, SOAIF could be
required to maximize a social welfare function, which
could be identical to society’s perspective; and 4) maximiz-
ing the utility function of SOAIF’s bureaucrats—according
to this perspective, as many rehabilitation interventions
will be produced as is necessary to maximize power, pres-
tige and income of the functionaries of the pension funds.
Consequences for study designs are discussed.
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Pharmacoeconomic and quality of life analyses are becom-
ing more familiar and hence more important to marketing
and reimbursement. The use of piggyback studies as an an-
